Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

ct of management fee reductions and lower utilization of supportive care drugs. The results of fiscal year 2007 also include restructuring and impairment charges of $15.1 million, a debt extinguishment loss of $12.9 million and an unrealized loss of $11.9 million related to our interest rate swap, for which cash flow hedge accounting was discontinued during 2007. In addition, interest expense increased $20.4 million due to higher borrowings outstanding during 2007.

The company currently anticipates that EBITDA for fiscal year 2008 will be approximately $220 million to $230 million. This estimate is a forward-looking statement and is subject to uncertainty including the results of the scheduled March 13, 2008 meeting of the Oncology Drug Advisory Committee of the FDA. The reader should refer to the Company's cautionary advice regarding forward-looking statements appearing elsewhere in this news release and in the Company's filings with the Securities and Exchange Commission.

Cash Flow

During the quarter ended December 31, 2007, operating cash flow provided was $74.2 million, compared to $3.9 million used in operations in the third quarter of 2007 which reflects lower regularly scheduled interest payments and increased receivable collections in the fourth quarter.

The Company generated operating cash flow of $164.7 million during 2007, compared to $20.5 million in 2006. The increase in operating cash flow was primarily due to working capital investments of $113.0 million during the first quarter of 2006, principally for inventory and accounts payable at the Company's distribution center as well as increased receivable collections during the current year.

On November 30, 2007, the company amended its senior secured credit facility to increase the maximum leverage and decrease the minimum interest coverage ratios required under the facility. The amended terms provide flexibility as the company responds to the adverse impact of reduced
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ATTLE,Nov.24/PRNewswire-FirstCall/--CellTherapeuti...ntatthe21stAnnualPiperJaffrayHealthCareConference....rkPalaceHotel. ,, CTIwillpresentonTuesday,Decem...eaudiowebcastofCTI,spresentationwillbeavailableat ...forreplayafterwards. , ,PiperJaffrayHealthCareCon...
(Date:11/23/2009)...N, Ill. You can think of it as origami very high... Illinois have developed a technique for fabricati...tructures from thin films by coupling photolithogr...y interactions. , The films, only a few microns t...sible with thicker pieces of the same material. ,...
(Date:11/23/2009)... consists of a two-dimensional carbon layer in whi...ttice, resembling a honeycomb. Carbon nanotubes ar... graphene sheets form graphite. Graphene boasts so...ear-resistant, an excellent thermal conductor, and...ess and ductility. In addition, graphene is imperm...
(Date:11/23/2009)...SSISSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioSci...uctdevelopmentcompanythatidentifiesandadvancesadiv...riousstagesofdevelopment,todayreportedthatCytopia(...luatingCYT387,apotent,orally-administeredJAK1/JAK2...chester,Minnesota.AproposaltomergeCytopiaintoYMhas...
Breaking Biology Technology:Water droplets direct self-assembly process in thin-film materials 2Polymer with honeycomb structure 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...-dose cohorts plus data from subsequent higher-dos..., Calif., March 18 InterMune, Inc. (Nasdaq: ITM...ical study of ITMN-191 (R7227) in combination with...ferred to as the INFORM-1 study, has been accepted... at the 44th Annual Meeting of the European Associ...
.... Wright, Co-Chair of the Alliance for Biosecurity...ied today before the House Labor, Health and Human...ee on the critical importance of developing drugs,... to protect Americans from bioterrorism and other ... countermeasures for many of the chemical, biologi...
...Marin Pharmaceutical Inc. (Nasdaq: BMRN ) announ...authorization (CTA) for BMN 110 or N-acetylgalacto...ment of the lysosomal storage disorder Mucopolysac...me, has been accepted by the United Kingdom Medici...A). BioMarin expects to initiate a Phase 1/2 clini...
Other Biology Technology:INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 2INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 3INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 4Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4
(Date:11/24/2009)...that may help gut bacteria bind to the gastrointes...c producers to identify strains that are likely to... to interact with cells lining the gut to have a b...n the gut they are more likely to stick around lon...e Juge from the Institute of Food Research. IFR i...
(Date:11/24/2009)...dical Toxicology (ACMT) have signed an agreement t...f Medical Toxicology (JMT), the official journal ...iously published by the University of Pennsylvania...an international, peer-reviewed journal, is dedica...al toxicology. The quarterly journal focuses on t...
(Date:11/24/2009)... of debate. A high-profile study a few years ago s...carbon from trees and leaves, evidence for a very ...systems. , But new research from the University ... Algae provide a much richer diet for fish and oth...his week in the Proceedings of the National Acade...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Minorities Less Likely to Have Blood Pressure Under Control 58190 1Minorities Less Likely to Have Blood Pressure Under Control 58190 2Minorities Less Likely to Have Blood Pressure Under Control 58190 3The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 1The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 2The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 3Aviva Family and Childrens Services Hosts Rededication Ceremony of the Newly Renovated Wallis Annenberg Center 58180 1Aviva Family and Childrens Services Hosts Rededication Ceremony of the Newly Renovated Wallis Annenberg Center 58180 2
...ilian personnel from the U.S. Armed Forces, as wel...aw enforcement and other first-responder personnel...dia have been encouraged to register and attend th...PED VII). The event will be held at Stafford Regio...uring May 19-21. , , The demonstration, which is ...
..., University of Alabama at Birmingham professor of...Prize for Outstanding Innovation in Life Sciences....salutes Weaver,s achievements in advancing underst...ough T cell research. , According to Weaver, our...and cancer, but when T cells overreact and turn on...
...ng diverse forests for multiple uses is important ...dy conducted in southwestern Oregon provides fores...en managing land for a variety objectives that may...te level of wood production with some wildlife hab...s cover and forage for a wider variety of wildlife...
Other Biology News:Demonstration Features Commercial Technology for Combating Terrorism 2UAB professor receives HudsonAlpha Innovation Prize 2Managing Douglas-fir forests for diversity 2
PARP Cleavage Immunoblotting Assay Kit from Upstate
...o-Sequencing is designed to aid sequence analysis ...ning sites (MCS) of M13 phage vectors (mp18/19) or...). The kit is used to create nested unidirectional...y moving the primer binding site on the vector clo...
MaxArray Rat Brain Tissue Slides from Invitrogen
...ion Kit, 100 reactions. Prepare circular DNA templ...ram quantities of template DNA from picogram amoun... for cycle sequencing without purification.Amplify...es, plaques, or purified circular (plasmid or M13)...
Biology Products: